Influenza Clinical Trials 2024

Influenza Clinical Trials 2024

Influenza research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in influenza clinical trials today.

Influenza Clinical Trials

Here are the 6 most popular medical studies for influenza

Stony Brook, New York

Group B for Influenza

Recruiting3 awardsPhase 4
Stony Brook, New York

Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu. Public health campaigns advocate widespread vaccination for the flu, and especially for high risk people. People with cancer are high risk, with an increased risk of developing complications from the flu, such as pneumonia, bronchitis, or worsening of other medical conditions. As part of their vaccination campaign, the CDC strongly encourages inpatients to be vaccinated prior to hospital discharge. Accordingly, Stony Brook Hospital has enacted a policy that mandates screening all hospital inpatients for vaccination prior to discharge. While physicians or patients can opt not to vaccinate, the default is to proceed. Surgical oncologists have several concerns about vaccinating their patients after major surgical procedures. Patients with cancer have impaired immunity, and the ability of our patients to mount an effective immune response to the vaccine is unclear. Conversely, due to their immunocompromised state, our patients may be more susceptible to complications from the vaccine, such as influenza-like-illness (ILI), or have higher rates of postoperative complications due to the additional immune challenge of the vaccine. Previous studies have evaluated the flu vaccine in patients receiving chemotherapy, or after organ transplantation, but the combination of cancer and major surgery remains unstudied. This is a collaborative study with Infectious Diseases and Microbiology to evaluate the response to the flu vaccine in patients with pancreatic or gastric cancer, soft tissue sarcoma or peritoneal surface disease (i.e. carcinomatosis from appendiceal or colon cancers). Patients will be randomly selected to receive the vaccine either 2 weeks preoperatively or postoperatively at the time of discharge. Serum antibody response, rates of ILI and post-op complications will be analyzed. The long term goal of this study is two-fold: to determine the optimal time to vaccinate this group of patients in relation to their surgery, and to improve compliance with vaccination.

Popular filter options for influenza trials

COVID-19 Clinical Trials

View 8 COVID-19 medical studies.

Phase 3 Influenza Clinical Trials

View 87 phase 3 influenza medical studies.

Influenza Clinical Trials With No Placebo

View 87 influenza medical studies that do not have a placebo group.

Paid Influenza Clinical Trials

View 87 influenza medical studies that offer remuneration.

Atlanta, Georgia

Virus Vaccine

Inactivated Influenza A/H5N1 Vaccine for Influenza

Recruiting2 awardsPhase 1 & 2
Atlanta, Georgia

This is a single center, open-label, Phase I/II study in up to 100 adult subjects, aged 18 years and older who are at occupational risk of exposure to live H5N1 viruses. This study is designed to investigate the safety, reactogenicity, and immunogenicity of two 90 µg doses of an investigational inactivated influenza A/H5N1 virus vaccine given approximately 28 days apart. A blood sample will be collected for immunogenicity evaluation prior to each vaccination. Subjects will maintain a memory aid (appendix C4 and C13) to record oral temperature and systemic and local AEs for 7 days after immunization. Subjects will be encouraged to take their temperature around the same time each day. All subjects will receive a safety follow-up telephone call at 1 to 3 days after each vaccination (approximately Day 2) to elicit any AE and concomitant medication information. Subjects will return to the clinic 7 days after each vaccination for assessment of AEs and concomitant medications, a targeted physical examination (if indicated), and review of the memory aid. At approximately Day 28 after the first vaccination, subjects will return to the clinic for evaluation of vital signs, blood sample collection and safety follow-up, confirmation of eligibility criteria and a second vaccination. Safety follow-up will be identical to that performed after the first vaccination. At approximately Day 56 (or about 28 days after the second vaccination), subjects will return to the clinic for immunogenicity blood sample collection, AE and concomitant medication assessment, and targeted physical examination and vital sign assessment (if indicated). At approximately Day 180 (6 months after the first vaccination), subjects will return to the clinic for a final immunogenicity blood sample collection and safety assessment. Blood samples collected prior to each vaccination (Days 0 and 28) and on Days 56 and 180 after the first vaccination will be tested at the CDC Influenza Division Laboratory for the levels of neutralizing and HAI antibodies and CMI responses. The primary outcome measures will be the frequencies and severities of AEs and the GMTS and proportions of subjects who achieve 4-fold rises in serum neutralizing and HAI titers against the influenza A/H5N1 virus on Day 56. Serum HAI and neutralizing antibody responses (including frequencies of 4 fold or greater rise in titer; GMTs; and proportions of subjects achieving protective titers of neutralizing antibody 1 month and 6 months after first dose) will also be assessed. A secondary outcome measure will be CMI responses evaluated 1 month after the receipt of each dose of vaccine and 6 months after the receipt of the first dose of vaccine.

View More Influenza Trials

See another 60 medical studies focused on influenza.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to influenza

What are the top hospitals conducting influenza research?

In the ongoing battle against influenza, several hospitals have emerged as leaders in conducting clinical trials to combat this infectious disease. The National Institutes of Health (NIH) Clinical Center in Bethesda is at the forefront, with four active influenza trials and a total of 15 conducted over time. Notably, their first recorded influenza trial dates back to 2008, showcasing their long-standing commitment to research in combating this seasonal menace. Another institution making strides is Johnson County Clin-Trials located in Lenexa. With four ongoing influenza studies and an impressive history of 19 previous trials, they have been dedicated to finding innovative solutions since their inaugural influenza trial in 2007.

Meanwhile, Meridian Clinical Research LLC based in Omaha has been contributing significantly with three active influenza trials and a track record of successfully completing 12 such studies since commencing research on the virus back in 2004. Closer home at CTI Clinical Research Center situated in Cincinnati; they may currently be running only three investigations but had made pioneering leap forward by recording its debut experiment concerning flu cases right from2022 onwards

Finally yet importantly Insight Therapeutics LLC located at Norfolk also actively carries out three current scientific inquiries into flu cases while already having accomplished progress through five prior tests upon beginning from2013 itself.

These esteemed hospitals serve as crucial hubs for advancements not just within local communities but across the nation's collective fight against this contagious respiratory illness. By participating or administering these clinical trials patients not only gain access to potentially life-saving treatments but also become integral contributors toward future breakthroughs that can ultimately help protect millions globally

Which are the best cities for influenza clinical trials?

In the realm of influenza clinical trials, several cities emerge as key players in advancing research and treatment. Miami, Florida leads with 24 ongoing trials investigating various approaches such as SSA: bivalent BNT162b2 (dose level 1) + QIV and mRNA-1010. Omaha, Nebraska follows closely behind with 18 active studies exploring interventions like Quadrivalent influenza modRNA vaccine. Rochester, New york also boasts 18 ongoing trials evaluating options such as VAX-MOM Intervention and Group 1: Quadrivalent Influenza mRNA Vaccine MRT5413 low dose. Lastly, San Diego, California contributes to the field with its 17 active trials examining advances like Group 2: Quadrivalent Influenza mRNA Vaccine MRT5407 dose level 2. These cities offer fertile ground for cutting-edge research aimed at improving our understanding and management of influenza.

Which are the top treatments for influenza being explored in clinical trials?

In the realm of influenza research, several top treatments are currently under exploration in clinical trials. The first on the list is the Influenza Vaccine, which shows promise with four active trials and a total of 13 all-time influenza trials since its debut in 2008. Another contender making waves is Baloxavir, involved in two ongoing studies and listed for the first time in 2020. Equally noteworthy is Baloxavir Marboxil, also participating in two active trials and accumulating nine all-time influenza trials since its introduction in 2016. Lastly, we have High Dose Quadrivalent Inactivated Influenza Vaccine joining the ranks with two current trials underway after being listed just this year (2021). As researchers delve deeper into these innovative treatments, hope grows stronger for improved outcomes against influenza outbreaks worldwide.

What are the most recent clinical trials for influenza?

Recent clinical trials for influenza have introduced promising advancements in the field. Notably, Group i and Influenza Vaccine studies have reached Phase 4, indicating their advanced stages of testing. Additionally, Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine and Fluad investigations are progressing well in Phase 2 trials. Furthermore, Arm 2 is currently undergoing Phase 1 testing to evaluate its potential effectiveness against influenza. With these ongoing studies focused on developing effective treatments and prevention strategies for influenza, there is hope for improved management of this infectious disease in the near future.

What influenza clinical trials were recently completed?

Several recent clinical trials focused on influenza have reached completion, representing significant advancements in combating this infectious disease. In August 2022, Seqirus successfully concluded a trial evaluating the efficacy of Experimental: aIIV-B Investigational as a single intramuscular dose. Preceding that, in July 2022, Seqirus completed a trial for aH5N6c. Other notable completed trials include FluGen Inc.'s investigation into the Cam2020 M2SR H3N2 influenza vaccine (June 2022), ModernaTX's mRNA-1073 study (May 2022), and Janssen Vaccines & Prevention B.V.'s Ad26.COV2.S research (November 2021). These studies stand testament to ongoing efforts to develop effective treatments against influenza and safeguard public health.